Musk’s new company could top a trillion?

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

Javier Rodriguez net worth and biography

Javier Rodriguez Biography and Net Worth

Director of Gilead Sciences

Mr. Rodriguez joined our Board in June 2020. Since 2019, Mr. Rodriguez has been the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout the United States and internationally. DaVita strives to improve patients’ quality of life through clinical innovation and integrated, personalized care. From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company’s business unit that treats patients with kidney failure and end-stage renal disease. Mr. Rodriguez has spent more than 20 years in various executive roles at DaVita, driving the company’s transformation for how kidney care is delivered. In 2019, Mr. Rodriguez was ranked No. 40 on the Modern Healthcare list of 100 Most Influential People in Healthcare and in 2015 was named one of the Top 10 Leaders by Hispanic Executive magazine. He currently serves as a member of the boards of directors of DaVita and the Denver Metro Chamber of Commerce.

What is Javier Rodriguez's net worth?: The estimated net worth of Javier Rodriguez is at least $78.80 million as of September 16th, 2024. Mr. Rodriguez owns 837,835 shares of Gilead Sciences stock worth more than $78,798,382 as of December 3rd. This net worth estimate does not reflect any other assets that Mr. Rodriguez may own. Learn More about Javier Rodriguez's net worth.
How do I contact Javier Rodriguez?: The corporate mailing address for Mr. Rodriguez and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Javier Rodriguez's contact information.
Has Javier Rodriguez been buying or selling shares of Gilead Sciences?: Javier Rodriguez has not been actively trading shares of Gilead Sciences within the last three months. Most recently, Javier Rodriguez sold 189 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $75.50, for a transaction totalling $14,269.50. Learn More on Javier Rodriguez's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 252,678 shares worth more than $22,650,360.76. The most recent insider tranaction occured on November, 27th when insider Merdad Parsey sold 164,211 shares worth more than $15,094,275.12. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/27/2024.

Javier Rodriguez Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/23/2020	Sell	189	$75.50	$14,269.50

Javier Rodriguez Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $94.05

$93.75

$94.39

50 Day Range

MA: $88.26

$82.21

$97.90

2 Week Range

Now: $94.05

$62.07

$98.90

Volume

2,076,341 shs

Average Volume

7,034,210 shs

Market Capitalization

$117.21 billion

P/E Ratio

1,045.00

Dividend Yield

3.33%

Beta

0.18